Hormone-Independent Mouse Mammary Adenocarcinomas with Different Metastatic Potential Exhibit Different Metabolic Signatures

• Published in: Biomolecules (Basel, Switzerland) Vol. 10; no. 9; p. 1242
• Main Authors: Bispo, Daniela, Fabris, Victoria, Lamb, Caroline A, Lanari, Claudia, Helguero, Luisa A, Gil, Ana M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.08.2020; MDPI
• Subjects: Acetic acid; Amino acids; Breast cancer; Breast carcinoma; Cancer; Cholesterol; endocrine breast cancer; Gene expression; Glucose metabolism; Glutathione; Glycolysis; hormone-independent growth; Lipid metabolism; Mammary gland; Medical prognosis; Medroxyprogesterone acetate; Metabolism; Metabolites; Metabolomics; Metastases; Metastasis; Mitochondria; murine models; NADH; NMR; Nuclear magnetic resonance; Phospholipids; Sphingomyelin; Tricarboxylic acid cycle; Tumors; NMR; metastatic potential; metabolomics; medroxyprogesterone acetate; murine models; hormone-independent growth; metabolism; endocrine breast cancer
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom10091242

The metabolic characteristics of metastatic and non-metastatic breast carcinomas remain poorly studied. In this work, untargeted Nuclear Magnetic Resonance (NMR) metabolomics was used to compare two medroxyprogesterone acetate (MPA)-induced mammary carcinomas lines with different metastatic abilities. Different metabolic signatures distinguished the non-metastatic (59-2-HI) and the metastatic (C7-2-HI) lines, with glucose, amino acid metabolism, nucleotide metabolism and lipid metabolism as the major affected pathways. Non-metastatic tumours appeared to be characterised by: (a) reduced glycolysis and tricarboxylic acid cycle (TCA) activities, possibly resulting in slower NADH biosynthesis and reduced mitochondrial transport chain activity and ATP synthesis; (b) glutamate accumulation possibly related to reduced glutathione activity and reduced mTORC1 activity; and (c) a clear shift to lower phosphoscholine/glycerophosphocholine ratios and sphingomyelin levels. Within each tumour line, metabolic profiles also differed significantly between tumours (i.e., mice). Metastatic tumours exhibited marked inter-tumour changes in polar compounds, some suggesting different glycolytic capacities. Such tumours also showed larger intra-tumour variations in metabolites involved in nucleotide and cholesterol/fatty acid metabolism, in tandem with less changes in TCA and phospholipid metabolism, compared to non-metastatic tumours. This study shows the valuable contribution of untargeted NMR metabolomics to characterise tumour metabolism, thus opening enticing opportunities to find metabolic markers related to metastatic ability in endocrine breast cancer.